Drugs / quadrivalent influenza vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05526716 | Sep 2022 → Jun 2023 | streptococcal pneumonia | Merck Sharp & Dohme LLC | Completed | Mixed |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2020-06-22 | Merck Sharp & Dohme LLC | Results Merck Announces That V114, Its Investigational 15-valent Pneumococcal Conjugate Vaccine, Met Safety and Immunogenicity Objectives in Initial Phase 3 Studies in Adults merck.com ↗
Results from the PNEU-FLU (V114-021) study in healthy adults 50 years of age or older showed that V114 can be given concomitantly with the quadrivalent influenza vaccine. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2020-06-22 | Merck Sharp & Dohme LLC | Merck Announces That V114, Its Investigational 15-valent Pneumococcal Conjugate Vaccine, Met Safety and Immunogenicity Objectives in Initial Phase 3 Studies in Adults merck.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | quadrivalent influenza vaccine | “This phase 3 study evaluated the safety, tolerability, and immunogenicity of V116 when administered concomitantly with quadrivalent influenza vaccine (QIV) in adults.” PMID 40714528 ↗ Jul 2025 |
| Known as | QIV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05526716 ↗ |
| Modality | Vaccine | “quadrivalent influenza vaccine (QIV)” NCT05526716 ↗ |
| Route | Intramuscular | “Participants will receive a single 0.5 mL IM injection of QIV” NCT05526716 ↗ |